Takeda
Von Willebrand disease – increasing awareness and access to vital care
November 4, 2025Medical Communications, Research and Development European Medicines Association, Haematology, Takeda, Von Willebrand Disease, clinical trials, disease awareness
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about Von Willebrand disease, its causes …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
September 23, 2025Research and Development HIV/AIDS, Hepatology, NHS, NICE, Oncology, Takeda, combination therapy, oncology
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment landscape and the impact of …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
Biomarkers used in trial to prevent systematic onset of Crohns Disease before it begins in Europe-first project
January 22, 2025Research and Development Crohns Disease, Crohsn, Gastrointestinal tract, Takeda, biomarkers, ibd, project
Takeda, a global biopharmaceutical company, is due to launch a project, INTERCEPT, which will use biomarkers to prevent symptomatic onset …
Takeda shares data from phase 3 trial of CIPD treatment
June 20, 2024Research and Development CIDP, Hyqvia, Neurology, Takeda, clinical trial
Takeda has announced data from the phase 3 ADVANCE-CIDP 3 trial, which assessed the safety and efficacy of Hyqvia (Immune …
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
March 21, 2024Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …
Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan
August 29, 2023Sales and Marketing Elahere, Immunogen, Oncology, Takeda
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company for the development and commercialisation …
Takeda and HUTCHMED’s cancer drug shown to prolong overall survival
June 16, 2023Research and Development HUTCHMED, Oncology, Takeda, colorectal cancer
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which is being developed by Japanese …
FDA grants Priority Review for Takeda’s cTTP treatment
May 17, 2023Research and Development Biologics License Application, Cardiology, FDA, Takeda, cTTP
Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application …
Takeda collaboration to optimise biopharmaceutical manufacturing announced
June 22, 2021Manufacturing and Production Takeda, collaboration, manufacturing
A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering (RCPE), InSilicoTrials, and the University …
Takeda’s lung cancer drug granted FDA priority review
April 29, 2021FDA, Takeda, lung cancer treatment, pharma, pharma news
The FDA has granted priority review for Takeda’s New Drug Application (NDA) for its mobocertinib drug for the treatment of …
Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio
March 10, 2021Research and Development Maverick, Takeda, cancer treatment
Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …
Takeda agree $856m deal with Ovid to take over soticlestat development
March 4, 2021Ovid, Takeda, epilepsy treatment, epiplepsy, soticlestat
Ovid Therapeutics and Takeda have agreed a deal worth up to $856 million, allowing the latter to take over development …
Takeda sells four diabetes products to Teijin Pharma for $1.25m
February 26, 2021Medical Communications Takeda
Takeda has entered into an agreement to transfer the assets, marketing rights, and, eventually, marketing authorisation associated with a portfolio …
Latest content
FibroFind appoints Lee Borthwick as CEO
